Goodwin advised Isomorphic Labs on its strategic research collaboration with Novartis. Isomorphic Labs has signed a strategic research collaboration with Novartis to discover small molecule therapeutics against...
You must be a Standard 1 Year member to access this content.
Goodwin advised Human Immunology Biosciences (HI-Bio) on the round. Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs),...
You must be a Standard 1 Year member to access this content.
Goodwin advised bit.bio on the agreement. BlueRock Therapeutics LP, a wholly owned, independently operated subsidiary of Bayer AG, and bit.bio announced a collaboration and option agreement for...
You must be a Standard 1 Year member to access this content.
Goodwin advised Moderna, Inc. on the deal. Moderna, Inc. (Nasdaq:MRNA) announced its strategic collaboration with Generation Bio Co. (Nasdaq:GBIO) to combine Moderna’s biological and technical expertise with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Envisagenics, Inc. on the deal. Envisagenics, Inc. announced a research collaboration agreement with Bristol Myers Squibb Company (NYSE: BMY). The multi-year collaboration will leverage...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Acadia Pharmaceutical on the deal while Wilson Sonsini represented Stoke Therapeutics. Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced its collaboration agreement with Stoke Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX:...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Goodwin Procter LLP advised Centessa Pharmaceuticals on the deal. Centessa Pharmaceuticals, a clinical-stage company employing its innovative asset-centric business model...
You must be a Standard 1 Year member to access this content.
